Kilkenny mother heartbroken after being denied access to Spinraza for her son

A local mother who’s been campaigning for access to Spinraza says they are ‘heartbroken’.

It’s after the HSE said it will not sanction the use of the drug for Spinal Muscular Atrophy claiming its too expensive.

However the company that makes it, Biogen, claims its pricing proposal is in line with what European countries have approved.

Carol Brennan from Kilkenny, who believes her 6 year old son could benefit from Spinraza, says price shouldn’t come into the equation when it comes to childrens health.

She says they are not going to stop here though.